Scientific AdvisorsOur Team
The Scientific Advisory Board (SAB) is comprised of a group of individuals that have significant scientific technical backgrounds in medical devices, diagnostics and other areas related to ANGLE’s products. SAB members provide strategic input, insight and expertise in the blood and cancer fields and also advise the Company on technical aspects in relation to platform development, product development and clinical studies as well as providing broader industry input.
Dr. Daniel Danila is an assistant attending physician at Memorial Hospital Cancer Center in New York. Dr. Danila also serves as an assistant with the Weill Cornell Medical College. Dr Danila’s primary research focuses on prostate cancer. Specifically, Dr. Danila is exploring a hypothesis that molecular profiling of CTCs can be used to assess biological determinants of the growth of prostate cancer tumors.
Brings to the SAB expertise in – development and adoption of CTCs as predictive biomarkers to help clinicians select appropriate treatments, prostate cancer and wide network of contacts in the field.
Dr George Hvichia is the original inventor of the core Parsortix technology and played a lead role in ANGLE’s Parsortix patents. Dr. Hvichia is an expert in microfluidic technology related to cell and particle separation and platform integration. Dr. Hvichia was the first person to recognise the combined principle of separation by size and deformability of rare cells in fluids, such as blood, and that microfluidic devices could be used to achieve this, even though manufacturing at the necessary tolerances was not possible at the time. This core technology yields low cost, efficient, single use and scalable micro-devices for use in the fields of Liquid Biopsy and Precision Medicine.
Brings to the SAB expertise in – microfluidics and biochips with ongoing thoughts and advice on development of the Parsortix system.
Dr. Joseph Khoury is a recognised expert in diagnostic pathology and has significant experience in the cytological and morphological analysis of cancer cells as well as molecular diagnostics and immunophenotyping. Dr. Khoury is a tenured Professor of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas and is the Executive Director of the MD Anderson Cancer Network for the Division of Pathology and Laboratory Medicine. Dr. Khoury is also the Director of the MD Anderson Clinical Immunohistochemistry Laboratory.
Brings to the SAB expertise in – diagnostic pathology and cytological and morphological analysis of cancer cells.
Prof. Adrian Newland (who is not related to ANGLE’s Chief Executive) is Professor of Haematology at Barts Health NHS Trust and Queen Mary University of London. Prof. Newland was also Director of Pathology for the Trust and Clinical Director of the North East London Cancer Network until 2018. Prof. Newland was President of the Royal College of Pathologists from 2005 to 2008 and the International Society of Hematology from 2014 to 2016. Prof. Newland chaired the National Blood Transfusion Committee and was pathology lead for NHS London. Prof. Newland is National Clinical Advisor in Pathology to NHS Improvement and Clinical Advisor to the Transforming Cancer Service Team in London.
Brings to the SAB expertise in – haematology, pathology, cancer diagnostics and NICE.
Dr. Reuben is a Professor in the Department of Hematopathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas. Dr. Reuben is a leading authority and has conducted significant research on circulating tumour cell subsets, including those with epithelial and mesenchymal phenotypes and their clinical relevance to minimal residual disease in breast cancer.
Brings to the SAB expertise in – knowledge and understanding of CTCs, breast cancer and wide network of contacts in the field.
Mr Shaw is a Consultant Urological Surgeon at University College Hospital in London and is a clinical academic with a strong interest in prostate cancer diagnostics and treatment. Having completed an M.D. in prostate cancer at the University of London investigating circulating tumour cells in prostate cancer, and subsequently completed four years as a lecturer at the University of Cambridge, Mr Shaw has published widely on prostate cancer and is currently an honorary senior lecturer at University College and Queen Mary College of the University of London.
Brings to the SAB expertise in – prostate cancer diagnostics and treatment.
Dr. Clive Stanway is currently an independent drug discovery and development advisor to several companies. Dr. Stanway was until 2018 Chief Scientific Officer of Cancer Research UK’s Commercial Partnerships which is responsible for the development and commercialisation of research innovations. Dr. Stanway is an expert in cancer drug discovery and a key part of his former role was working closely with major pharmaceutical partners. Dr. Stanway has extensive knowledge and experience of cancer research, detailed understanding of the drug discovery and development process, and worldwide contacts with major pharma development groups.
Brings to the SAB expertise in – cancer drug discovery and development and major pharma networks.
Dr. Harold Swerdlow is currently Senior Director of NGS R&D at DNA Electronics (DNAe) in London. His role there involves managing Next-Generation Sequencing (NGS) technology and product development for an initial sepsis diagnostic offering. Dr. Swerdlow is a leading expert in NGS and recently served as a consultant for both ONI (Oxford Nanoimaging), a super-resolution microscopy company, and Nuclera, a DNA synthesis start-up after being Head of NGS Technology Development at LGC Genomics.
Brings to the SAB expertise in – next generation sequencing, genomics and system integration.
Prof. Ashok Venkitaraman holds the Ursula Zoellner Professorship of Cancer Research at the University of Cambridge, and is Director of the Medical Research Council’s Cancer Cell Unit and Joint Director of the Medical Research Council Hutchison Cancer Research Centre. Prof. Venkitaraman’s research has helped to elucidate the connections between chromosome instability and the genesis of epithelial cancers.
Brings to the SAB expertise in – cancer cell biology and personalised cancer care.